explore -WSS

explore

author：comprehensive 2025-09-27 21:27:37 - browse：36329

Why are addiction treatments so hard to get? Can small companies compete in obesity? And since when is “Series E” a thing in biotech?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. For the entirety of the opioid overdose epidemic, the U.S. has had readily available tools that are proven to save lives. STAT’s Lev Facher joins us to explain his reporting on why virtually every sector of American society is standing in the way of their use. We also discuss the latest news in the life sciences, including the haves and have-nots of venture capital, and the race to develop effective oral treatments for obesity.

For more on what we cover, here’s the story on addiction medicine; here’s the latest on biotech financing; here’s more on Novo Nordisk’s oral obesity treatment; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： STAT Virtual Event: JPM Recap, Live!

WSS

Did you have Obamacare on your GOP debate bingo card?

FDA advisers vote against ALS treatment from BrainStorm

Why do women spend more than men on medical expenses?

FDA early review: GLP

Stories you might have missed in 2023: health, science, medicine

Menendez indictment could see pharma lose a key ally

leisure time

explore

explore

Alkermes shareholders re

Sudafed saga points to U.S. issues with evaluating older drugs

Novavax promises a turnaround & Lilly roils the obesity market

Covid vaccines: Private market messier than government rollout

Alkermes shareholders re

Gene therapy denied for Afghan refugee whose father aided U.S.

Supreme Court strikes down use of affirmative action

Medicare drug price negotiation program allowed for now

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Menendez indictment could see pharma lose a key ally

focus

Ascension's ugly legal battle over care for poor patients in Texas

Medicaid, Medicare dual

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Medicare drug price negotiation program allowed for now

Intercept Pharmaceuticals sells itself for less than $1 billion

JPM pitch from hospitals? Revenue streams outside of patient care

hotspot

hotspot

focus

entertainment